Physician profile
Douglas Johnson
NPI 1700869427
$568,478.94
in general payments reported to CMS, 2019-2025
28 companies · $63K in 2025
The $63K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100K · 2020: $31K · 2021: $41K · 2022: $67K · 2023: $109K · 2024: $159K · 2025: $63K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $260K · Travel and Lodging: $33K · Food and Beverage: $18K · Consulting Fee: $10K · Grant: $8,000 · Honoraria: $305 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $259,884.50 |
| Travel and Lodging | $33,321.36 |
| Food and Beverage | $18,065.06 |
| Consulting Fee | $10,483.00 |
| Grant | $8,000.00 |
| Honoraria | $305.30 |
| Education | $230.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $86,826.61 | 2019-2025 | |
| Lilly USA, LLC | $80,366.50 | 2019-2025 | Olumiant, Ebglyss, Taltz |
| Ucb, INC. | $73,885.42 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $65,884.95 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $46,850.01 | 2019-2025 | |
| Pfizer INC. | $43,097.36 | 2019-2025 | |
| Amgen INC. | $41,316.53 | 2019-2025 | Otezla, Otezla, Tavneos |
| Incyte Corporation | $22,894.67 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $20,273.11 | 2019-2025 | Ilumya |
| Celgene Corporation | $16,956.50 | 2019 | |
| Galderma Laboratories, L.P. | $16,323.08 | 2019-2025 | Nemluvio |
| Genzyme Corporation | $16,149.58 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $9,886.31 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $8,891.04 | 2021-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $7,767.25 | 2019-2024 | Siliq, Duobrii, Targretin |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $5,879.05 | 2019-2021 | |
| Dermavant Sciences, INC. | $2,813.31 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $1,048.74 | 2023-2024 | Zoryve |
| Janssen Biotech, INC. | $468.12 | 2020-2025 | Tremfya, Simponi, Simponi Aria |
| Genentech USA, INC. | $202.32 | 2019-2024 | Xolair |
| Regeneron Pharmaceuticals, INC. | $160.88 | 2022 | |
| Sanofi US Services INC. | $134.99 | 2025 | |
| Sanofi-Aventis U.S. LLC | $117.36 | 2019-2020 | |
| Almirall LLC | $96.80 | 2020 | |
| Smith+Nephew, INC. | $68.82 | 2020 | |
| Blueprint Medicines Corporation | $63.00 | 2025 | |
| Organon LLC | $31.16 | 2025 | Vtama |
| Ani Pharmaceuticals, INC. | $25.47 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.